# Erasca news releases

- **Website:** https://www.erasca.com
- **Location:** San Diego, CA, United States
- **Releases:** 2
- **First release:** November 18, 2026
- **Most recent:** November 20, 2026
- **Categories:** Nasdaq:ERAS
- **Web page:** https://www.connectively.us/news-releases/erasca
- **RSS:** https://www.connectively.us/news-releases/erasca/rss.xml

## Releases

### [Erasca Reports Broad and Robust Phase 1 Clinical Efficacy and Favorable Safety Data for Pan-RAS Molecular Glue ERAS-0015](https://www.connectively.us/news-releases/erasca-reports-broad-and-robust-phase-1-clinical-efficacy-and)

November 20, 2026 · Nasdaq:ERAS

ERAS-0015 at 32 mg QD achieved 44% confirmed ORR in 2L+ KRAS G12X PDAC, despite heavy pretreatment (84% in the 3L+ setting) and a high proportion of G12R mutations (44% of patients) ERAS-0015 at 32 mg QD achieved 69% confirmed ORR in 2L+ KRAS G12D or G12V PDAC ERAS-0015 at 32 mg…

### [Erasca Enters into Clinical Collaboration with Bristol Myers Squibb to Evaluate ERAS-0015 in Clinical Study with Navlimetostat](https://www.connectively.us/news-releases/erasca-enters-into-clinical-collaboration-with-bristol-myers-squibb-to)

November 18, 2026 · Nasdaq:ERAS

ERAS-0015 will be evaluated with PRMT5 inhibitor navlimetostat in MTAP-deleted pancreatic cancer in Phase 1/2 trial BMS will sponsor the clinical trial and Erasca will supply ERAS-0015 SAN DIEGO, Nov. 17, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc.
